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Abstract: PURPOSE: The aim of this study was to evaluate the feasibility of attenuation correction
(AC) for cardiac (18)F-labelled fluorodeoxyglucose (FDG) positron emission tomography (PET) using
MR-based attenuation maps. METHODS: We included 23 patients with no known cardiac history under-
going whole-body FDG PET/CT imaging for oncological indications on a PET/CT scanner using time-
of-flight (TOF) and subsequent whole-body PET/MR imaging on an investigational hybrid PET/MRI
scanner. Data sets from PET/MRI (with and without TOF) were reconstructed using MR AC and
semi-quantitative segmental (20-segment model) myocardial tracer uptake (per cent of maximum) and
compared to PET/CT which was reconstructed using CT AC and served as standard of reference. RE-
SULTS: Excellent correlations were found for regional uptake values between PET/CT and PET/MRI
with TOF (n = 460 segments in 23 patients; r = 0.913; p < 0.0001) with narrow Bland-Altman lim-
its of agreement (-8.5 to +12.6 %). Correlation coefficients were slightly lower between PET/CT and
PET/MRI without TOF (n = 460 segments in 23 patients; r = 0.851; p < 0.0001) with broader Bland-
Altman limits of agreement (-12.5 to +15.0 %). PET/MRI with and without TOF showed minimal
underestimation of tracer uptake (-2.08 and -1.29 %, respectively), compared to PET/CT. CONCLU-
SION: Relative myocardial FDG uptake obtained from MR-based attenuation corrected FDG PET is
highly comparable to standard CT-based attenuation corrected FDG PET, suggesting interchangeability
of both AC techniques.
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Abstract
Purpose The aim of this study was to evaluate the feasibility
of attenuation correction (AC) for cardiac 18F-labelled
fluorodeoxyglucose (FDG) positron emission tomography
(PET) using MR-based attenuation maps.
Methods We included 23 patients with no known cardiac his-
tory undergoing whole-body FDG PET/CT imaging for onco-
logical indications on a PET/CT scanner using time-of-flight
(TOF) and subsequent whole-body PET/MR imaging on an
investigational hybrid PET/MRI scanner. Data sets from PET/
MRI (with and without TOF) were reconstructed using MR
AC and semi-quantitative segmental (20-segment model)
myocardial tracer uptake (per cent of maximum) and com-
pared to PET/CT which was reconstructed using CT AC and
served as standard of reference.
Results Excellent correlations were found for regional uptake
values between PET/CT and PET/MRI with TOF (n=460
segments in 23 patients; r=0.913; p<0.0001) with narrow
Bland-Altman limits of agreement (−8.5 to +12.6 %). Corre-
lation coefficients were slightly lower between PET/CT and
PET/MRI without TOF (n=460 segments in 23 patients; r=
0.851; p<0.0001) with broader Bland-Altman limits of
agreement (−12.5 to +15.0 %). PET/MRI with and without
TOF showedminimal underestimation of tracer uptake (−2.08
and −1.29 %, respectively), compared to PET/CT.
Conclusion Relative myocardial FDG uptake obtained from
MR-based attenuation corrected FDG PET is highly compa-
rable to standard CT-based attenuation corrected FDG PET,
suggesting interchangeability of both AC techniques.
Keywords Cardiac imaging . Attenuation correction . PET/
MRI . Hybrid imaging
Introduction
Over the past decades, hybrid positron emission tomography
(PET)/CT scanners have evolved as an important non-
invasive imaging tool for cardiac imaging mainly because of
the added value of co-localization of functional and/or meta-
bolic parameters acquired by PET imaging with anatomical
information as depicted by coronary CT angiography [1].
PET/MRI scanners have very recently been introduced into
the clinical arena as a novel type of hybrid scanner. While it is
yet too early to appreciate the full spectrum of potential ben-
efits of this technology for cardiac imaging, it may be expect-
ed that the superior assessment of left ventricular functional
parameters through MRI due to excellent soft tissue charac-
terization and improved localization of myocardial fibrosis
and/or scar tissue through late contrast enhancement could
provide valuable added information complementary to meta-
bolic data assessed by PET [2, 3].
However, hybrid PET/MRI scanners lack the firmly
established methods for attenuation correction (AC) provided
by a dedicated CT component as in hybrid PET/CT systems.
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Calculation of accurate AC maps has been rapidly identified
as a major challenge for hybrid PET/MRI systems and several
approaches are currently used [4]. One approach is based on
water-weighted and fat-weighted data sets derived from aDix-
on MRI sequence, enabling classification of each voxel as air,
lungs, fat or soft tissue [5, 6]. Bone tissue is ignored with this
method as it is almost impossible to segment from such data
sets. Neglecting bone tissue, however, may result in an under-
estimation of tissue attenuation which may be of particular
concern for PET imaging of the heart which is encompassed
by the rib cage and lies adjacent to the spinal column. Several
studies have shown that in PET/MRI, application of MR-
derived AC has led to a substantial underestimation of uptake
of 18F-labelled fluorodeoxyglucose (FDG) into metastases
compared to PET/CT [7, 8]. A recent publication briefly
assessed this issue by assessing absolute cardiac FDG uptake
through regional measurement of the maximum standardized
uptake value (SUVmax) suggesting that AC derived fromMRI
and CT may be interchangeable [9].
However, no comprehensive data are available on the per-
formance of AC from MRI compared to CT for cardiac PET/
MRI scanning, neither for metabolic nor for perfusion imag-
ing. Thus, the objective of the present study was to evaluate
the feasibility of AC for cardiac FDG PET using MR-based




A total of 43 oncological patients undergoing a clinical whole-
body FDG scan on a standard PET/CT scanner were addition-
ally scanned on an investigative simultaneous PET/MRI scan-
ner. In a retrospective subanalysis we identified 23 patients
(13 men) with spontaneous myocardial accumulation of
FDG (Fig. 1). The study protocol was approved by the local
Ethics Committee, and all subjects signed a written informed
consent form (KEK 2013–0358, Swissmedic: 2013-MD-
0035, ClinicalTrials.gov Identifier: NCT02071706).
First, a standard PET/CT scan with TOF was obtained
followed by a comparative examination on a GE Signa PET/
MRI hybrid whole-body scanner (GE Healthcare, Waukesha,
WI, USA), which was not CEmarked and not approved by the
US Food and Drug Administration at the time of this study.
During PET/CT scans the arms were elevated over the head,
while during PET/MRI scans the arms were positioned at the
side. Patients were instructed to fast for at least 4 h before
FDG injection. The administered dose was 3 MBq/kg if the
body weight was less than 85 kg or 3.5 MBq/kg otherwise.
The mean time interval between start of the PET/CTand PET/
MRI was 46±17 min (range 26–86 min).
PET/CT imaging
PET/CT images were obtained from a state-of-the-art TOF
PET/CT device (Discovery D690, GE Healthcare, Waukesha,
WI, USA). The Discovery 690 combines a lutetium yttrium
orthosilicate (LYSO) block detector designed PET tomograph
with a 64-slice CT scanner. The system further has a powerful
computing platform implementing three-dimensional (3-D)
PET iterative reconstruction algorithms. These algorithms
can account for TOF information [10]. First, a non-contrast
whole-body low-dose CT scan was acquired with a tube volt-
age 120–140 kV, tube current with automated dose modula-
tion 60–440 mA/slice, collimation 64×0.625, pitch 0.984:1,
rotation time 0.5 s, coverage speed 78mm/s, transaxial field of
view (FOV) 70 cm and images with a transverse pixel size of
0.625 and a slice thickness of 3.75 mm reconstructed in the
axial, coronal and sagittal planes. PET data were then acquired
in 3-D TOF mode with scan duration of 2 min per bed posi-
tion, an overlap of bed positions of 23 % and an axial FOVof
153 mm. PET/CT data sets were reconstructed through AC of
the emission data with attenuation maps obtained from the
initial low-dose CT scan and were then iteratively reconstruct-
ed [matrix size 256×256, Fourier rebinning (VIPmode), VUE
Point FX (3-D) with 3 iterations and 18 subsets] [11].
Fig. 1 Whole-body FDG PET/MRI follow-up scan of a patient with
former multiple myeloma, showing spontaneous FDG accumulation in
the heart
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PET/MR imaging
After PET/CT acquisition, patients were transferred to the
PET/MRI scanner which is located in an adjacent room to
the PET/CT. The scanner comprises a 3-T wide-bore MRI
system with an MR-compatible TOF PET detector ring
installed between the body and gradient coils. The detector
ring consists of 28 modules, each one containing 4×15 sub-
blocks and covering roughly 64.5 × 250 mm2. In each sub-
block, an array of 3 × 2 silicon photomultipliers is paired with
an array of 4 × 3 LYSO scintillator crystals, each measuring
3.95 × 5.3 × 25.0 mm3. The PET transaxial and axial FOVare
600 and 250 mm, respectively. The best achievable resolving
time of the TOF detector is less than 400 ps [12]. PET imaging
time per bed position was 3 min. During continuous PET
image acquisition, several MRI sequences were acquired si-
multaneously. First, a whole-body, dual-echo gradient recalled
echo sequence (LAVA Flex) was acquired for PET AC with
the body coil. From this, several reconstructions (in-phase,
out-of-phase images, fat and water images) can be provided
for the readers [5, 13, 14].
The following parameters were used as recently reported
[11]: repetition time (TR): 4.056 ms, echo time (TE) in-phase:
2.232 ms, TE out-of-phase: 1.116 ms, flip angle (FA): 12°,
FOV 500 × 375 mm (frequency × phase), acquisition matrix
256 × 128, 1 slab with 64 × 5.2 mm thick axial slices, voxel
size: 1.95 × 2.93 mm and 1 average. Additionally, the basic
whole-body protocol always consisted at least of a higher
resolution LAVA Flex, a T2-weighted fast recovery fast spin-
echo (FRFSE) and a T2-weighted FRFSE with fat saturation
and respiratory trigger for the thorax (not simultaneously with
PET). The standard patient radiofrequency (RF) coil set-up
always included the 19-channel head and neck unit, the 16-
channel upper and lower anterior arrays and the 14-channel
central matrix array (GE Healthcare, Waukesha, WI, USA).
MR-based attenuation correction
MR AC uses a head atlas for the patient’s head region and a
four-class segmentation algorithm which differentiates air,
lung and continuous fat/water segmentation for other body
regions. In a first step the body contour is identified. In the
next step the specific tissue classes (e.g. air, lung and soft
tissue) are segmented with the aid of the prior knowledge of
the bed positions. Next, a continuous fat-water method uses
the Dixon-basedMR fat and water images to allow continuous
variation between fat and water classification. In the final step
TOF PET data are used for truncation completion [15–17].
Table 1 Patient baseline
characteristics and reason for
referral
Patient Diagnosis Age (years) BMI (kg/m2)
1 Metastasizing adenocarcinoma of the lung 50 21.3
2 Hodgkin’s lymphoma 30 22.8
3 Adenocarcinoma of the lung 58 22.1
4 Sigma carcinoma 55 28.7
5 Metastasizing carcinoma of the breast 53 26.0
6 Squamous cell carcinoma of the parotid gland 58 25.1
7 Carcinoma of the tongue 51 23.3
8 Multiple myeloma 57 21.7
9 Non-Hodgkin’s lymphoma 41 25.4
10 Squamous cell carcinoma of the tonsil 57 19.8
11 Rectum carcinoma 51 19.0
12 Mantle cell non-Hodgkin’s lymphoma 54 22.6
13 Invasive ductal carcinoma of the breast 41 18.3
14 Adenocarcinoma of the lung 52 28.3
15 B-cell lymphoma 73 26.2
16 Metastasizing melanoma 45 30.8
17 Squamous cell carcinoma of the cheek 62 26.8
18 Nodular melanoma of the thigh 71 29.4
19 Metastasizing melanoma 63 31.0
20 Squamous cell carcinoma of the lung 64 21.6
21 Mucoepidermoid carcinoma of the sublingual gland 48 28.6
22 Carcinoma of the prostate 70 31.6
23 Anal carcinoma 70 25.3
BMI body mass index
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To assess the impact of TOF on MR attenuation maps, all
PET images from PET/MRI were reconstructed without TOF
and with TOF for each data set. The first applied method,
VUE Point HD (VPHD), is based on a fully 3-D ordered
subsets expectation maximization (3-D OSEM) iterative re-
construction algorithm, which incorporates all corrections
(scatter, random, dead time, attenuation and normalization)
but ignores the TOF information. The second applied method,
VUE Point FX (VPFX), is similar to VPHD but takes the TOF
information into account.
PET analysis
PET data were analysed using a commercially available soft-
ware package (Myovation, GE Healthcare, Waukesha, WI,
USA) on a dedicated imaging workstation (Xeleris 3, GE
Healthcare, Waukesha, WI, USA). Polar maps were normal-
ized to 100 % peak activity and the segmental relative radio-
tracer uptake was computed using a 20-segment model for the
left ventricle [18]. The effect of CTACmay vary substantially
among different myocardial regions owing to anatomical non-
uniformity or misalignment, as demonstrated by Ficaro et al.
[19] and Lautamäki et al. [20]. In order to assess such varia-
tions among myocardial regions we also assigned the 20
segments of the left ventricular myocardium to five regions
of the left ventricle for regional comparison: apex (segments
19 and 20), anterior (segments 1, 2, 7, 8, 13 and 14), septal
(segments 3, 9 and 15), lateral (segments 5, 6, 11, 12, 17 and
18) and inferior (segments 4, 10 and 16) [21]. Analysis was
performed with CTAC and repeated with MR AC (with and
without TOF).
Statistical analysis
Values are expressed as mean±standard deviation. Pearson
correlation and Bland-Altman analysis (BA) [22] were used
for evaluation of the continuous values. All statistical analyses
were performed using a commercially available software
package (IBM SPSS Statistics, Version 22). A p value<0.05
was considered statistically significant.
Results
Baseline characteristics and reason for referral for each indi-
vidual study patient are given in Table 1. The mean age was
55±10 years (range 30–73 years), and mean body mass index
was 25±3.8 kg/m2. All 23 patient data sets were successfully
Fig. 2 Linear regression analysis
and Bland-Altman plots for com-
parison of segmental per cent
FDG uptake from PET/MRI ver-
sus PET/CT using PET/MRI with
TOF (a) or without TOF (b). The
histogram on the y-axis in the
Bland-Altman plots depicts the
frequency of differences in seg-
mental uptake
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analysed from both scanners, resulting in 460 segments and 5
regions. Of note, no patient had a history of coronary artery
disease.
Compared to PET/CT AC, PET/MRI AC with TOF and
PET/MRI without TOF both showedminimal, but statistically
significant, underestimation of tracer uptake of −2.08 and
−1.29 %, respectively (both p<0.0001) (Fig. 2a, b). Compar-
ison of segmental FDG uptake between PET/CT and PET/
MRI (both with TOF) revealed an excellent correlation (n=
460; r=0.913; p<0.0001) with narrow limits of agreement
(−12.61 to +8.45 %) (Fig. 2a). After switching off the TOF
information in PET/MRI the correlation was slightly weaker
(r=0.851; p<0.0001) with slightly broader limits of agree-
ment (−15.09 to +12.50 %) (Fig. 2b).
Similarly, the correlations between regional radiotracer up-
take values obtained from PET/MRI AC with TOF and PET/
CT AC were highly significant, with correlation coefficients
ranging from 0.891 to 0.946 (Table 2) and narrow limits of
agreement (apex, +7.14 to −13.92 %, mean −3.38; anterior, +
10.38 to −13.88 %, mean −1.65; septal, +7.85 to −8.81 %,
mean −0.48; lateral, +7.77 to −13.36 %, mean −2.78; inferior,
+6.02 to −10.46 %, mean −2.22). Similarly, excellent correla-
tions between regional FDG uptake values obtained from
PET/MRI without TOF and PET/CT AC were found with
coefficients ranging from 0.812 to 0.928 (Table 2) and narrow
limits of agreement (apex, +8.96 to −11.41 %, mean −1.28;
anterior, +15.74 to −16.84 %, mean −0.55; septal, +11.07 to
−12.03 %, mean −0.48; lateral, +10.38 to −16.80 %, mean
−3.21; inferior, +11.69 to −10.46 %, mean +0.26). These find-
ings are consistent with a visual reading of the polar maps
which showed comparable perfusion distribution in between
MR AC without TOF, MR AC with TOF and CT AC with
TOF (Fig. 3). For a more detailed analysis a segment-wise
evaluation is summarized in the supplementary data.
Discussion
Hybrid PET/MRI is emerging as a novel diagnostic modality
for cardiac imaging with the promise of playing an exciting
role in multiple cardiovascular applications [2, 23]. Contrary
to PET/CT, however, hybrid PET/MRI does not directly pro-
vide the data needed for AC as the signal intensity in the MR
image is not directly related to photon attenuation. Current
techniques for MR-based AC rely on attenuation maps de-
rived from image segmentation where the MR image is seg-
mented into different tissues with similar tissue characteristics
for attenuation coefficients to be assigned based on known
attenuation coefficients [4, 5]. The present study aims at eval-
uating the feasibility of such a segmentation-based approach
for cardiac FDG PET by comparing relative segmental
Table 2 Correlation coefficients and BA agreement between CTAC andMRACwith TOF and between CTAC andMRACwithout TOF for various
myocardial regions (p<0.0001 for all correlations)
Apical Anterior Septal Lateral Inferior
CTAC CTAC CTAC CTAC CTAC
MR AC with TOF CC 0.918 0.897 0.946 0.891 0.922
BA +7.14 to–13.92 +10.38 to–13.88 +7.85 to–8.81 +7.77 to–3.36 +6.02 to–0.46
Meana –3.38 –1.65 –0.48 –2.78 –2.22
MR AC without TOF CC 0.928 0.812 0.903 0.821 0.861
BA +8.96 to–11.41 +15.74 to–16.84 +11.07 to–12.03 +10.38 to–16.80 +11.69 to–10.46
Meana –1.28 –0.55 –0.48 –3.21 +0.26
AC attenuation correction, CC correlation coefficients, TOF time of flight, BA Bland-Altman limits of agreement (%)
aMean difference between PET/MRI and PET/CT (i.e. PET/MRI − PET/CT)
Fig. 3 Polar maps representing
segmental per cent myocardial
FDG uptake in a single patient,
reconstructed using MR AC
without TOF, MR AC with TOF
or CTAC with TOF
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myocardial tracer uptake obtained from a novel hybrid PET/
MRI device versus standard PET/CT.
Our results demonstrate an excellent comparability among
the two AC techniques with relative segmental tracer uptake
from PET/MRI highly correlating with results from PET/CT
and with minimal underestimation by PET/MRI and narrow
limits of agreement within a clinically acceptable range [24].
Furthermore, we evaluated the potential added value from
integrating PET TOF information into the reconstruction of
PET/MR images. Conventional non-TOF PET detector sys-
tems assume that photons arriving at two opposite detectors,
within a predefined timing window of a few nanoseconds,
originated from an annihilation event that could have occurred
anywhere along the line of response between the two detectors
with equal probability. ATOF PET detector system can mea-
sure the time difference between the two photons arriving at
opposite detectors with a certain resolution [25, 26]. As a
result, TOF allows better localization of annihilation, enables
better lesion detectability and improves the signal to noise
ratio [27]. This could potentially contribute to overcoming
some of the limitations of AC in PET/MRI, such as segmen-
tation error and artefacts due to bone or metal implants, which
may lead to inconsistencies inMRACmaps, thereby affecting
diagnostic accuracy of PET [28]. In the present study, the
addition of TOF information for AC in PET/MRI substantially
improved the correlation with AC of PET/CT, notably with
narrower BA limits of agreement compared to PET/MRI AC
without TOF. Similarly, comparison of regional uptake values
revealed a slightly superior agreement of PET/MRI AC with
TOF particularly in the anterior, inferior and lateral segments.
Of note, for MR AC without TOF BA analysis revealed a
slight overestimation of tracer uptake in the inferior wall. By
contrast MR AC with TOF led to a small underestimation of
tracer uptake which was consistent across all regions. Thus, if
available in modern PET systems, the additional information
from TOF should be integrated into the process of AC.
In summary, albeit by using Dixon sequences for MR AC
no specific correction for photon attenuation from bone tissue
could be applied, our findings suggest interchangeability of
MR AC with conventional CT AC for the non-quantitative
assessment of cardiac FDG uptake as it is routinely performed
for evaluation of myocardial viability. Whether addition of
attenuation information for bone tissue, for example through
application of ultrashort echo time MRI sequences, would
have improved our results remains to be evaluated [29]. These
findings are in line with a recent publication evaluating abso-
lute cardiac FDG uptake from MR-based AC as assessed by
SUVmax values [8]. Our findings may not necessarily apply to
other cardiac PET applications such as perfusion scanning
including qualitative and quantitative perfusion assessment
and functional parameters from gated acquisition.
Although our findings have to be confirmed in future stud-
ies in larger patient populations and in a real-world clinical
setting, they have important preliminary implications for fu-
ture cardiac PET/MRI protocols, because validation of MR
AC is imperative for rendering the CT scans unnecessary in
the future, thereby setting the grounds for hybrid cardiac PET/
MRI to play out its full potential in the future.
We acknowledge several limitations of our study. First, we
analysed FDG data sets that were acquired in an oncological
setting with spontaneous accumulation of FDG in the heart
rather than from specific cardiac viability evaluation. Second,
PET/MRI AC and PET/CT AC were not acquired simulta-
neously and the time interval between the two scans may have
potentially affected the comparability of tracer uptake due to
inhomogeneous tracer washout in different cardiac segments.
Furthermore, the scanners used in the present study differ in
terms of system design, and image data sets obtained are spe-
cifically dependent on the applied reconstruction algorithms
and acquisition durations. However, it appears that this has not
affected the agreement between the two methods, which
strengthens the results of our study. Finally, our results may
at least in part be scanner specific and therefore not necessarily
applicable to other scanners from other vendors.
Conclusion
Relative myocardial FDG uptake obtained from MR-based
attenuation-corrected FDG PET is highly comparable to stan-
dard CT-based attenuation-corrected FDG PET, suggesting
interchangeability of both AC techniques.
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